Literature DB >> 9836890

Can screening for IgG antibodies against Helicobacter pylori be used in clinical practice? Omit endoscopy in seropositive or seronegative patients?

B F Werdmuller1, A B V/der Putten, R A Veenendaal, C B Lamers, R J Loffeld.   

Abstract

The objective of this study was to test the feasibility of a screening strategy for IgG antibodies against Helicobacter pylori in patients presenting with upper abdominal complaints. Biopsy specimens were taken for histological and microbiological investigations from consecutive patients undergoing upper gastrointestinal endoscopy. In addition, a serum sample was taken for detection of IgG antibodies against Helicobacter pylori, using an ELISA technique. Serum samples from 1294 consecutive patients were available. IgG antibodies against Helicobacter pylori were present in 622 patients (48%), the remaining 671 (52%) were negative. If endoscopy had been omitted in seronegative patients below the age of 45 years, this would have resulted in 234 patients not endoscoped. However, it can be assumed that 62 of these patients would undergo endoscopy because of recurrent complaints due to underlying disease or abnormality. Therefore 182 of 1294 (14%) of endoscopies would have been avoided. Application of this strategy on the total group of seronegatives would save 353 of 1294 (27.3%) endoscopies. If endoscopy had been omitted in seropositive cases below the age of 45 years, and these patients were treated with anti-Helicobacter therapy, an initial 145 endoscopies would have been avoided. However, 26 of these patients would undergo endoscopy because of persistent complaints due to underlying disease. Therefore 119 (9%) endoscopies would have been avoided. Applying this strategy in the total group of seropositives would have saved 434 of 1294 endoscopies (34%). Applying the IgG screening strategy in all patients would result in a significant number of endoscopies being avoided in the seropositive group, 434 versus 353 (P < 0.001). In conclusion, omitting endoscopy in seropositive cases, regardless of age, can reduce the workload more than omitting endoscopy in seronegative cases: 34% fewer endoscopies versus 27%.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9836890     DOI: 10.1023/a:1026683026028

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  12 in total

1.  Screening dyspepsia by serology to Helicobacter pylori.

Authors:  G M Sobala; J E Crabtree; J A Pentith; B J Rathbone; T M Shallcross; J I Wyatt; M F Dixon; R V Heatley; A T Axon
Journal:  Lancet       Date:  1991-07-13       Impact factor: 79.321

2.  Diagnostic value of an immunoassay to detect anti Campylobacter pylori antibodies in non-ulcer dyspepsia.

Authors:  R J Loffeld; E Stobberingh; J A Flendrig; J P van Spreeuwel; J W Arends
Journal:  Lancet       Date:  1989-05-27       Impact factor: 79.321

3.  Prospective screening of dyspeptic patients by Helicobacter pylori serology.

Authors:  P Patel; S Khulusi; M A Mendall; R Lloyd; R Jazrawi; J D Maxwell; T C Northfield
Journal:  Lancet       Date:  1995-11-18       Impact factor: 79.321

4.  Helicobacter pylori and upper gastrointestinal disease: a survey of gastroenterologists in the United Kingdom.

Authors:  R Milne; R P Logan; D Harwood; J J Misiewicz; D Forman
Journal:  Gut       Date:  1995-09       Impact factor: 23.059

5.  Long term serological surveillance after treatment of Helicobacter pylori infection.

Authors:  R A Veenendaal; A S Peña; J L Meijer; H P Endtz; M M van der Est; W van Duijn; F Eulderink; J Kreuning; C B Lamers
Journal:  Gut       Date:  1991-11       Impact factor: 23.059

6.  Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori.

Authors:  T U Kosunen; K Seppälä; S Sarna; P Sipponen
Journal:  Lancet       Date:  1992-04-11       Impact factor: 79.321

7.  Value of serology (ELISA and immunoblotting) for the diagnosis of Campylobacter pylori infection.

Authors:  A S Peña; H P Endtz; G J Offerhaus; A Hoogenboom-Verdegaal; W van Duijn; N de Vargas; G den Hartog; J Kreuning; J van der Reyden; R P Mouton
Journal:  Digestion       Date:  1989       Impact factor: 3.216

8.  Possible role of Helicobacter pylori serology in reducing endoscopy workload.

Authors:  T C Tham; N McLaughlin; D F Hughes; M Ferguson; J J Crosbie; M Madden; S Namnyak; F A O'Connor
Journal:  Postgrad Med J       Date:  1994-11       Impact factor: 2.401

9.  Long-term prospective study of Helicobacter pylori in nonulcer dyspepsia.

Authors:  C McCarthy; S Patchett; R M Collins; S Beattie; C Keane; C O'Morain
Journal:  Dig Dis Sci       Date:  1995-01       Impact factor: 3.199

10.  Long-term sequelae of Helicobacter pylori gastritis.

Authors:  E J Kuipers; A M Uyterlinde; A S Peña; R Roosendaal; G Pals; G F Nelis; H P Festen; S G Meuwissen
Journal:  Lancet       Date:  1995-06-17       Impact factor: 79.321

View more
  3 in total

1.  Evaluation of three commercial serological tests with different methodologies to assess Helicobacter pylori infection.

Authors:  A van Der Ende; R W van Der Hulst; P Roorda; G N Tytgat; J Dankert
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

Review 2.  A rational approach to uninvestigated dyspepsia in primary care: review of the literature.

Authors:  N L A Arents; J C Thijs; J H Kleibeuker
Journal:  Postgrad Med J       Date:  2002-12       Impact factor: 2.401

Review 3.  Non-invasive diagnostic tests for Helicobacter pylori infection.

Authors:  Lawrence Mj Best; Yemisi Takwoingi; Sulman Siddique; Abiram Selladurai; Akash Gandhi; Benjamin Low; Mohammad Yaghoobi; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2018-03-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.